Ujash Sheth1, Matthew Saltzman2. 1. Department of Orthopaedic Surgery, Northwestern University, 259 East Erie, 13th Floor, Chicago, IL, 60611, USA. usheth@qmed.ca. 2. Department of Orthopaedic Surgery, Northwestern University, 259 East Erie, 13th Floor, Chicago, IL, 60611, USA.
Abstract
PURPOSE OF REVIEW: Our understanding of the reverse total shoulder arthroplasty (RTSA) has grown exponentially since Grammont first introduced his design in 1985. There are a multitude of implant-related variables to consider when performing RTSA. The purpose of this article is to provide a review of these design considerations. RECENT FINDINGS: Current literature demonstrates that the traditional Grammont prosthesis has over 90% survivorship at 10 years. Despite these promising results, there have been concerns raised over the significant rate of scapular notching observed. As a result, the traditional RTSA design has been modified to minimize this complication and maximize impingement-free motion. Modern RTSA designs with a cementless, curved, short-stemmed eccentric onlay humeral component combined with a large, lateralized glenosphere placed in 10° of inferior tilt with > 3.5 mm of inferior overhang have been found to provide excellent results. However, all implant design features must be considered on a case-by-case basis to optimize outcome for each patient. Humeral and glenoid implant design variables have evolved as the biomechanics of RTSA have been further elucidated. Consideration of these variables allows the surgeon to maximize joint efficiency, improve impingement-free range of motion, decrease the risk of scapular notching, preserve bone stock, and minimize the risk of instability.
PURPOSE OF REVIEW: Our understanding of the reverse total shoulder arthroplasty (RTSA) has grown exponentially since Grammont first introduced his design in 1985. There are a multitude of implant-related variables to consider when performing RTSA. The purpose of this article is to provide a review of these design considerations. RECENT FINDINGS: Current literature demonstrates that the traditional Grammont prosthesis has over 90% survivorship at 10 years. Despite these promising results, there have been concerns raised over the significant rate of scapular notching observed. As a result, the traditional RTSA design has been modified to minimize this complication and maximize impingement-free motion. Modern RTSA designs with a cementless, curved, short-stemmed eccentric onlay humeral component combined with a large, lateralized glenosphere placed in 10° of inferior tilt with > 3.5 mm of inferior overhang have been found to provide excellent results. However, all implant design features must be considered on a case-by-case basis to optimize outcome for each patient. Humeral and glenoid implant design variables have evolved as the biomechanics of RTSA have been further elucidated. Consideration of these variables allows the surgeon to maximize joint efficiency, improve impingement-free range of motion, decrease the risk of scapular notching, preserve bone stock, and minimize the risk of instability.
Authors: Sergio Gutiérrez; Charles A Comiskey; Zong-Ping Luo; Derek R Pupello; Mark A Frankle Journal: J Bone Joint Surg Am Date: 2008-12 Impact factor: 5.284
Authors: Bryan Wall; Laurent Nové-Josserand; Daniel P O'Connor; T Bradley Edwards; Gilles Walch Journal: J Bone Joint Surg Am Date: 2007-07 Impact factor: 5.284
Authors: Philipp Moroder; Manuel Urvoy; Patric Raiss; Jean-David Werthel; Doruk Akgün; Jean Chaoui; Paul Siegert Journal: Clin Orthop Relat Res Date: 2022-03-01 Impact factor: 4.755
Authors: Christopher Como; Clarissa LeVasseur; Gillian Kane; Ajinkya Rai; Maria Munsch; Alexandra Gabrielli; Jonathan Hughes; William Anderst; Albert Lin Journal: J Biomech Date: 2022-03-12 Impact factor: 2.789
Authors: Georg Siebenbürger; Evi Fleischhacker; Ulla Stumpf; Tobias Helfen; Wolfgang Böcker; Ben Ockert Journal: Geriatr Orthop Surg Rehabil Date: 2021-10-24
Authors: Julia K Frank; Paul Siegert; Fabian Plachel; Philipp R Heuberer; Stephanie Huber; Jakob E Schanda Journal: J Clin Med Date: 2022-03-10 Impact factor: 4.241